Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07206121 · ClinicalTrials.gov registry record · NA

Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery

A NA study of Breast Cancer and Breast-conserving Surgery, sponsored by Innoblative Designs.

Recruiting
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT07206121: Recruiting NA study of Breast Cancer and Breast-conserving Surgery, sponsored by Innoblative Designs.

NCT07206121 is a NA study of Breast Cancer and Breast-conserving Surgery that is actively recruiting participants, run by Innoblative Designs. The registered enrollment target is 10 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07206121, a NA study of Breast Cancer and Breast-conserving Surgery, is actively recruiting participants, sponsored by Innoblative Designs.

RECRUITING
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This study aims to assess the safety and clinical accuracy of the SIRA-1000, SIRA® RFA Electrosurgical Device in ablating margins post-lumpectomy in patients undergoing breast conserving surgery for breast cancer. Radiofrequency ablation, or RFA, uses radio waves to create heat, that in turn, causes deliberate controlled damage to the tissue surrounding where the tumor was located. You may hear your doctor refer to this as the 'margins'. Your doctor is using this treatment to help destroy remaining cancer cells in the margins around the site of the lump.

Primary Outcome

Assess the occurrence adverse events and to evaluate the impact of RFA on healing process.

Interventions

  • DEVICE Radiofrequency ablation alone
  • DEVICE Radiofrequency ablation Electrosurgical Device

Study Locations (1)

Texas

  • University of Texas Medical Branch at Galveston, TX - Galveston

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2026-02-10
Est. Completion 2032-02-06
Phase NA
Innoblative Designs

1 total trials

What NCT07206121 shows while recruiting

NCT07206121 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower).

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiofrequency ablation alone is the first listed.

NCT07206121 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT07206121 about?

NCT07206121 is a clinical study titled "Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery". This study aims to assess the safety and clinical accuracy of the SIRA-1000, SIRA® RFA Electrosurgical Device in ablating margins post-lumpectomy in patients undergoing breast conserving surgery for breast cancer. Radiofrequency ablation, or RFA, uses radio waves to create heat, that in turn, causes...

What is the current status of trial NCT07206121?

This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2026-02-10. Estimated completion is 2032-02-06.

What conditions does trial NCT07206121 study?

This clinical trial studies the following conditions: Breast Cancer, Breast-conserving Surgery, Breast Cancer - Infiltrating Ductal Carcinoma, ER/PR+Her2neu, Grade I, II, III.

What interventions are being tested in trial NCT07206121?

The interventions under investigation include: Radiofrequency ablation alone (DEVICE), Radiofrequency ablation Electrosurgical Device (DEVICE).

Who is sponsoring clinical trial NCT07206121?

This trial is sponsored by Innoblative Designs, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07206121 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07206121's enrollment target sits among peer trials

10 1177th of 1224 higher than 36 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07206121, the US trial registry maintained by the National Library of Medicine. NCT07206121 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.